Green Cross: Institutions Net Buy 144,763 Shares Over 5 Days... Stock Price at 431,000 Won (+7.48%)

As of 9:30 a.m. on November 10, shares of Green Cross are trading at 431,000 won, up 7.48% from the previous day. The trading volume stands at 514,911 shares, which is 67.89% of the previous day's volume. Green Cross is known as a pharmaceutical company specializing in blood products and vaccines.

On November 5, Jin Heung-guk, a researcher at Korea Investment & Securities, stated, "With contract manufacturing of COVID-19 vaccines, operating profit is expected to increase by an additional 600 billion won next year. At the end of the year, there is also momentum from the expected submission of the IVIG FDA BLA. Starting in 2023, sales of IVIG to the U.S. will begin, enabling the company to generate nearly 400 billion won in operating cash flow annually through 2025, making it promising from a long-term investment perspective. As short-term momentum, the submission of the IVIG BLA and the signing of the main contract for the COVID-19 vaccine are expected, so continued attention is warranted despite the recent sharp rise in the stock price." He set the target price for Green Cross at 500,000 won.

Over the past five days, individual investors have been net sellers of 70,322 shares of Green Cross, while foreign investors and institutions have been net sellers of 19,898 shares and net buyers of 144,763 shares, respectively.

※ Source: AI investment assistant AI Rassiro

※ This article was automatically generated in real time by a news generation algorithm jointly developed by Asia Economy and the financial AI specialist company Thinkpool.

This content was produced with the assistance of AI translation services.